New Nanotechnology for Herpes Prevention

Modified nanoparticles may be used as antiviral agents against herpes simplex virus 1 and 2 (HSV-1) (HSV-2).

The Center for the Biology of Chronic Disease (CBCD), recently learned that there is a promising new approach to fighting the oral herpes virus (HSV-1). According to a paper published in the journal, PLoS One, entitled Tin Oxide Nanowires Suppress Herpes Simplex Virus-1 Entry and Cell-to-Cell Membrane Fusion. "The advent of nanotechnology has ushered in the use of modified nanoparticles as potential antiviral agents against diseases such as herpes simplex virus 1 and 2 (HSV-1) (HSV-2)."

The paper goes on to say, "tin oxide (SnO(2)) nanowires (can be) an effective treatment against HSV-1 infection. SnO(2) nanowires work as a carrier of negatively charged structures that compete with HSV-1 attachment to cell bound heparan sulfate (HS), therefore inhibiting entry and subsequent cell-to-cell spread."

The CBCD watches the development of antiviral nanotechnology with great interest, and agrees with the authors when they state, "This new approach can be developed into a novel form of broad-spectrum antiviral therapy, especially since HS has been shown to serve as a cellular co-receptor for a number of other viruses as well, including the respiratory syncytial virus, adeno-associated virus type 2, and human papilloma virus."

Genital herpes is a sexually transmitted disease (STD) caused by the herpes simplex viruses type 1 (HSV-1) or type 2 (HSV-2)

The CBCD would like to make clear, however, that antiviral nanotechnology is still in its infancy, and until it is readily available to the public, there remains no cure for any type of herpes infection. This includes both oral as well as genital herpes.

After the first infection, the virus goes to sleep (that is, becomes dormant) in the nerve tissues in the face. Sometimes, the virus later "wakes up" (reactivates), causing a herpes outbreak. When symptoms occur, they typically appear as one or more blisters on or around the genitals, rectum or mouth. The blisters break and leave painful sores that may take two to four weeks to heal.

As noted above, after an initial period of activity where there can be up to 5 major outbreaks in a year, the herpes virus establishes what scientists call a latent infection. When a virus is latent, it acts as if it is asleep or dormant. When the immune system weakens, however, the herpes virus can "wake up" and become active again.

The best defense against a latent herpes infection is a healthy immune system.

That's why the CBCD would like to point out a Herpes remedy that helps the immune system target the latent herpes virus (HSV).

"The key to your health is to reduce the level of the chronic viruses in your body to harmless levels." - Dr. Hanan Polansky

The name of that antiviral remedy is Gene-Eden-VIR. It is an all-natural product scientifically designed to help the human body maintain low concentrations of the latent herpes virus.

Gene-Eden-VIR is effective against the latent, oral and genital herpes viruses. Each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent forms of both HSV-1 and HSV-2.

Gene-Eden-VIR is safe. It has been on the market for over three years, and in that time, no side effects were reported. Each capsule contains a patented formula of five all natural ingredients including selenium, camellia sinesis extract, quercetin, cinnamomum extract, and licorice extract. In addition, each bottle is GMP Certified.

Gene-Eden-VIR is sold online through the Gene-Eden website. Each bottle of Gene-Eden-VIR (a one month's supply) costs $42.99.

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes virus, and that is scientifically backed by published material, visit the Gene-Eden-VIR website.

Note: This press release was first issued by The Center for the Biology of Chronic Disease (CBCD), a not-for-profit organization that specializes in researching the biology of foreign DNA.